For superficial infantile hemangiomas (superficial hemangiomas) that are in the proliferative phase within 1 year of age, early topical medication (small superficial HOIs should be treated in an early proliferative phase) can be used to control The hemangiomas should be treated in an early proliferative phase to control further development, promote regression, and relieve the psychological stress of the parents. Clinically available medications include 5% imiquimod cream, 0.5% timolol maleate eye drops, and propranolol oil or emulsion. Timolol maleate is a non-selective β-adrenergic receptor blocker, with effects similar to propranolol, but eight times stronger than propranolol. Ni et al. first reported the successful treatment of a 4-month-old infant with an episcleral hemangioma with timolol maleate eye drops. chakkittakandiyil et al. treated 73 children with timolol maleate eye drops for a mean of 3.4 ± 2.7 months. Oranje et al. reported that topical application of 0.5% timolol maleate eye drops (1-4 months) treated 20 children, except for 3 cases with no improvement in deep hemangioma, the remaining 7 children began to regress slowly after the lesion growth was controlled. Hu Li et al. compared the efficacy and safety of two topical drugs, 5% imiquimod cream and 0.5% timolol maleate eye drops, on superficial infantile hemangioma (IH) in the proliferative stage, and the topical 5% imiquimod cream group generally began to take effect 1 to 3 weeks after topical application, with a mean onset of effect of 14 days and a treatment efficiency of 81.4%. 0.5% timolol maleate eye drops took effect 3 d to 3 weeks after topical application, with a mean onset of effect of 8 days. The average onset of action was 8 days, with a treatment efficiency of 88.9%. After topical application of imiquimod cream, skin reactions may occur to varying degrees, including erythema, peeling, breakout, crusting and superficial scarring. It is believed that timolol maleate has a relatively rapid onset of action, promotes a higher degree of lesion color fading, and has fewer adverse effects, and can be the topical drug of choice for the treatment of proliferative superficial hemangiomas. How to use 0.5% timolol maleate eye drops: 3 times a day at 8 h interval (6 am, 2 pm, 10 pm), apply the drops to the surface of the tumor with a thin cotton swab moistened with the drops and keep it moist for 10 min. How to use 0.5% timolol maleate gel or cream: 3 times a day at 8 h interval (6 am, 2 pm, 10 pm), apply the gel with a thin cotton swab moistened with the drops and keep it moist for 10 min. Dip a cotton swab into the gel or cream and apply it evenly on the surface of the hemangioma tumor. After application, a film will be formed, so do not remove it and wash it off for the second time. Precautions before use: Cardiac ultrasound examination is required before use to exclude heart disease; exclude history of asthma. It is contraindicated in the following patients: (1) bronchial asthma or history of bronchial asthma; (2) severe chronic obstructive pulmonary disease; (3) sinus bradycardia; (4) II-III degree atrioventricular block; (5) refractory cardiac insufficiency; (6) cardiogenic shock; (7) hypersensitivity to this product. Timolol maleate eye drops have been proved to be effective in the treatment of superficial hemangioma, but the aqueous solution is inconvenient to use, easily evaporates, and causes dryness and peeling of the skin with long-term use. To overcome the above shortcomings, Zheng Jiawei’s group and Lin Xiaoxi’s group developed timolol ointment or gel respectively, which is more permeable and convenient to use, and has been clinically tried with good effect and generally welcomed.